Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

INTRODUCTION: The clinical efficacy and safety of ceftolozane/tazobactam for the treatment of ventilated hospital-acquired bacterial pneumonia (vHABP) and ventilator-associated bacterial pneumonia (VABP) has been demonstrated in the phase III randomised controlled trial ASPECT-NP. However, there are...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Infect Dis Ther
Päätekijät: Naik, Jaesh, Puzniak, Laura, Critchlow, Simone, Elsea, David, Dillon, Ryan James, Yang, Joe
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2021
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034281/
https://ncbi.nlm.nih.gov/pubmed/33837518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-021-00436-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia